0	11	DNA-binding	dna-binding	JJ
12	19	studies	study	NNS
20	22	of	of	IN
23	26	the	the	DT
27	39	Epstein-Barr	epstein-barr	JJ
40	45	virus	virus	NN
46	53	nuclear	nuclear	JJ
54	61	antigen	antigen	NN
62	63	2	2	CD
64	65	(	(	(
65	71	EBNA-2	ebna-2	NN
71	72	)	)	)
72	73	:	:	:
74	82	evidence	evidence	NN
83	86	for	for	IN
87	94	complex	complex	NN
95	104	formation	formation	NN
105	107	by	by	IN
108	114	latent	latent	JJ
115	123	membrane	membrane	NN
124	131	protein	protein	NN
132	136	gene	gene	NN
137	153	promoter-binding	promoter-binding	JJ
154	162	proteins	protein	NNS
163	165	in	in	IN
166	181	EBNA-2-positive	ebna-2-positive	JJ
182	186	cell	cell	NN
187	192	lines	line	NNS
192	193	.	.	.

195	198	The	the	DT
199	211	Epstein-Barr	epstein-barr	JJ
212	217	virus	virus	NN
218	219	(	(	(
219	222	EBV	EBV	NNP
222	223	)	)	)
224	231	nuclear	nuclear	JJ
232	239	antigen	antigen	NN
240	241	2	2	CD
242	243	(	(	(
243	249	EBNA-2	ebna-2	NN
249	250	)	)	)
251	258	protein	protein	NN
259	261	is	be	VBZ
262	271	essential	essential	JJ
272	275	for	for	IN
276	279	the	the	DT
280	295	immortalization	immortalization	NN
296	298	of	of	IN
299	304	human	human	JJ
305	312	primary	primary	JJ
313	314	B	b	NN
315	320	cells	cell	NNS
321	323	by	by	IN
324	327	EBV	EBV	NNP
327	328	.	.	.

329	335	EBNA-2	ebna-2	NN
336	351	trans-activates	trans-activate	VBZ
352	360	cellular	cellular	JJ
361	364	and	and	CC
365	370	viral	viral	JJ
371	376	genes	gene	NNS
377	381	like	like	IN
382	386	CD23	CD23	NNP
386	387	,	,	,
388	393	c-fgr	c-fgr	NN
393	394	,	,	,
395	401	latent	latent	JJ
402	410	membrane	membrane	NN
411	418	protein	protein	NN
419	420	1	1	CD
421	422	(	(	(
422	426	LMP1	lmp1	NN
426	427	)	)	)
428	431	and	and	CC
432	440	terminal	terminal	JJ
441	448	protein	protein	NN
449	450	1	1	CD
451	452	(	(	(
452	455	TP1	tp1	NN
455	456	)	)	)
456	457	.	.	.

458	474	Trans-activation	Trans-activation	NNP
475	477	of	of	IN
478	481	the	the	DT
482	485	TP1	tp1	NN
486	494	promoter	promoter	NN
495	498	and	and	CC
499	501	of	of	IN
502	505	the	the	DT
506	511	BamHI	BamHI	NNP
512	513	C	C	NNP
514	522	promoter	promoter	NN
523	526	has	have	VBZ
527	534	already	already	RB
535	539	been	be	VBN
540	552	investigated	investigate	VBN
553	555	in	in	IN
556	562	detail	detail	NN
563	566	and	and	CC
567	574	appears	appear	VBZ
575	577	to	to	TO
578	580	be	be	VB
581	589	mediated	mediate	VBN
590	593	via	via	IN
594	609	protein-protein	protein-protein	JJ
610	622	interactions	interaction	NNS
623	626	and	and	CC
627	630	not	not	RB
631	633	by	by	IN
634	640	direct	direct	JJ
641	648	binding	binding	NN
649	651	of	of	IN
652	658	EBNA-2	ebna-2	NN
659	663	type	type	NN
664	665	A	A	NNP
666	667	(	(	(
667	669	of	of	IN
670	673	EBV	EBV	NNP
674	678	type	type	NN
679	680	1	1	CD
680	681	)	)	)
682	684	to	to	TO
685	688	the	the	DT
689	692	DNA	dna	NN
692	693	.	.	.

694	700	EBNA-2	ebna-2	NN
701	703	is	be	VBZ
704	708	able	able	JJ
709	711	to	to	TO
712	726	trans-activate	trans-activate	VB
727	730	the	the	DT
731	741	expression	expression	NN
742	744	of	of	IN
745	748	the	the	DT
749	752	LMP	LMP	NNP
753	757	gene	gene	NN
758	760	in	in	IN
761	768	several	several	JJ
769	773	cell	cell	NN
774	779	lines	line	NNS
779	780	.	.	.

781	788	Various	various	JJ
789	796	reports	report	NNS
797	801	have	have	VBP
802	812	delineated	delineate	VBN
813	816	the	the	DT
817	827	cis-acting	cis-acting	JJ
828	836	elements	element	NNS
837	839	of	of	IN
840	843	the	the	DT
844	847	LMP	LMP	NNP
848	856	promoter	promoter	NN
857	864	through	through	IN
865	870	which	which	WDT
871	877	EBNA-2	ebna-2	NN
878	886	mediates	mediate	VBZ
887	903	trans-activation	trans-activation	NN
903	904	.	.	.

905	907	To	to	TO
908	917	determine	determine	VB
918	925	whether	whether	IN
926	932	EBNA-2	ebna-2	NN
933	937	also	also	RB
938	953	trans-activates	trans-activate	VBZ
954	957	the	the	DT
958	961	LMP	LMP	NNP
962	970	promoter	promoter	NN
971	973	by	by	IN
974	989	protein-protein	protein-protein	JJ
990	1002	interactions	interaction	NNS
1002	1003	,	,	,
1004	1006	we	we	PRP
1007	1016	performed	perform	VBD
1017	1018	a	a	DT
1019	1025	series	series	NN
1026	1028	of	of	IN
1029	1032	gel	gel	NN
1033	1044	retardation	retardation	NN
1045	1051	assays	assay	NNS
1052	1055	and	and	CC
1056	1067	competition	competition	NN
1068	1079	experiments	experiment	NNS
1080	1084	with	with	IN
1085	1088	LMP	LMP	NNP
1089	1097	promoter	promoter	NN
1098	1107	fragments	fragment	NNS
1108	1110	of	of	IN
1111	1120	different	different	JJ
1121	1126	sizes	size	NNS
1126	1127	.	.	.

1128	1130	We	we	PRP
1131	1141	determined	determine	VBD
1142	1146	that	that	IN
1147	1150	the	the	DT
1151	1166	protein-binding	protein-binding	JJ
1167	1173	region	region	NN
1174	1176	on	on	IN
1177	1180	the	the	DT
1181	1184	LMP	LMP	NNP
1185	1193	promoter	promoter	NN
1194	1197	was	be	VBD
1198	1204	within	within	IN
1205	1206	a	a	DT
1207	1209	42	42	CD
1210	1212	bp	bp	NN
1213	1221	fragment	fragment	NN
1222	1234	encompassing	encompass	VBG
1235	1246	nucleotides	nucleotide	NNS
1247	1251	-135	-135	CD
1252	1254	to	to	TO
1255	1259	-176	-176	CD
1260	1268	relative	relative	JJ
1269	1271	to	to	TO
1272	1275	the	the	DT
1276	1279	LMP	LMP	NNP
1280	1295	transcriptional	transcriptional	JJ
1296	1301	start	start	NN
1302	1306	site	site	NN
1306	1307	.	.	.

1308	1312	None	none	NN
1313	1315	of	of	IN
1316	1319	the	the	DT
1320	1323	DNA	dna	NN
1324	1333	fragments	fragment	NNS
1334	1346	investigated	investigate	VBN
1347	1356	indicated	indicate	VBD
1357	1368	interaction	interaction	NN
1369	1371	of	of	IN
1372	1378	EBNA-2	ebna-2	NN
1379	1383	with	with	IN
1384	1387	the	the	DT
1388	1391	DNA	dna	NN
1392	1395	via	via	IN
1396	1411	protein-protein	protein-protein	JJ
1412	1424	interactions	interaction	NNS
1424	1425	.	.	.

1426	1428	No	no	DT
1429	1440	significant	significant	JJ
1441	1452	differences	difference	NNS
1453	1460	between	between	IN
1461	1476	EBNA-2-positive	ebna-2-positive	JJ
1477	1480	and	and	CC
1481	1496	EBNA-2-negative	ebna-2-negative	JJ
1497	1504	nuclear	nuclear	JJ
1505	1513	extracts	extract	NNS
1514	1519	could	could	MD
1520	1522	be	be	VB
1523	1527	seen	see	VBN
1528	1530	in	in	IN
1531	1534	the	the	DT
1535	1538	gel	gel	NN
1539	1550	retardation	retardation	NN
1551	1556	assay	assay	NN
1557	1562	under	under	IN
1563	1573	conditions	condition	NNS
1574	1578	that	that	WDT
1579	1586	clearly	clearly	RB
1587	1593	showed	show	VBD
1594	1601	binding	binding	NN
1602	1604	of	of	IN
1605	1612	EBNA-2A	EBNA-2A	NNP
1613	1615	to	to	TO
1616	1619	the	the	DT
1620	1623	TP1	tp1	NN
1624	1632	promoter	promoter	NN
1632	1633	.	.	.

1634	1641	However	however	RB
1641	1642	,	,	,
1643	1651	analysis	analysis	NN
1652	1654	of	of	IN
1655	1662	sucrose	sucrose	NN
1663	1671	gradient	gradient	NN
1672	1681	fractions	fraction	NNS
1682	1684	in	in	IN
1685	1688	the	the	DT
1689	1692	gel	gel	NN
1693	1704	retardation	retardation	NN
1705	1710	assay	assay	NN
1711	1719	provided	provide	VBD
1720	1728	evidence	evidence	NN
1729	1733	that	that	IN
1734	1737	the	the	DT
1738	1741	LMP	LMP	NNP
1742	1758	promoter-binding	promoter-binding	JJ
1759	1767	proteins	protein	NNS
1768	1772	form	form	VBP
1773	1774	a	a	DT
1775	1782	complex	complex	NN
1783	1785	of	of	IN
1786	1792	higher	high	JJR
1793	1797	M(r)	m(r)	NN
1798	1800	in	in	IN
1801	1816	EBNA-2-positive	ebna-2-positive	JJ
1817	1821	cell	cell	NN
1822	1830	extracts	extract	NNS
1830	1831	.	.	.

1832	1837	These	these	DT
1838	1847	complexes	complex	NNS
1848	1852	were	be	VBD
1853	1862	destroyed	destroy	VBN
1863	1865	by	by	IN
1866	1875	detergent	detergent	NN
1875	1876	.	.	.

1877	1879	We	we	PRP
1880	1886	deduce	deduce	VBP
1887	1891	from	from	IN
1892	1897	these	these	DT
1898	1905	results	result	NNS
1906	1910	that	that	IN
1911	1926	EBNA-2-positive	ebna-2-positive	JJ
1927	1932	cells	cell	NNS
1933	1938	might	might	MD
1939	1945	indeed	indeed	RB
1946	1953	contain	contain	VB
1954	1962	specific	specific	JJ
1963	1972	complexes	complex	NNS
1973	1978	bound	bind	VBN
1979	1981	to	to	TO
1982	1985	the	the	DT
1986	1989	LMP	LMP	NNP
1990	1998	promoter	promoter	NN
1999	2004	which	which	WDT
2005	2008	are	be	VBP
2008	2009	,	,	,
2010	2017	however	however	RB
2017	2018	,	,	,
2019	2022	too	too	RB
2023	2029	labile	labile	JJ
2030	2032	to	to	TO
2033	2035	be	be	VB
2036	2044	detected	detect	VBN
2045	2047	in	in	IN
2048	2049	a	a	DT
2050	2058	standard	standard	JJ
2059	2062	gel	gel	NN
2063	2074	retardation	retardation	NN
2075	2080	assay	assay	NN
2080	2081	.	.	.